REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Sep 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-09-01

Reporting Person: Landry Robert E (SVP Finance & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-01	Common Stock	M	3000	$272.7	Acquired	10099	Direct
2017-09-01	Common Stock	F	1631	$501.29	Disposed	8468	Direct
2017-09-01	Common Stock	F	706	$501.29	Disposed	7762	Direct
2017-09-05	Common Stock	S	100	$500.33	Disposed	7662	Direct
2017-09-05	Common Stock	S	89	$501.88	Disposed	7573	Direct
2017-09-06	Common Stock	S	100	$496.51	Disposed	7473	Direct
2017-09-06	Common Stock	S	74	$496.52	Disposed	7399	Direct
2017-09-06	Common Stock	S	100	$496.86	Disposed	7299	Direct
2017-09-06	Common Stock	S	100	$498.25	Disposed	7199	Direct
2017-09-06	Common Stock	S	100	$499.69	Disposed	7099	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-09-01	Non-Qualified Stock Option (right to buy)	$272.7	M	3000	Disposed	2023-09-09	Common Stock (3000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	83	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.